Edition:
United States

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

72.15USD
12:55pm EDT
Change (% chg)

$-0.60 (-0.82%)
Prev Close
$72.75
Open
$72.40
Day's High
$73.20
Day's Low
$72.00
Volume
26,558
Avg. Vol
110,427
52-wk High
$87.05
52-wk Low
$31.70

Latest Key Developments (Source: Significant Developments)

Foundation Medicine - Co, Guardant Health ‍Announced Agreement To Settle False Advertising Challenges
Tuesday, 13 Mar 2018 04:05pm EDT 

March 13 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE - CO, GUARDANT HEALTH ‍ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER.  Full Article

Foundation Medicine Reports Qtrly ‍loss Per Share $1.05
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK.SEES FY 2018 REVENUE $200 MILLION TO $220 MILLION.Q4 REVENUE $48.9 MILLION VERSUS $28.8 MILLION.QTRLY ‍LOSS PER SHARE $1.05.EXPECTS OPERATING EXPENSES WILL BE IN RANGE OF $250 MILLION TO $260 MILLION IN 2018​.Q4 REVENUE VIEW $46.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd
Monday, 5 Mar 2018 04:47pm EST 

March 5 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING.FOUNDATION MEDICINE INC - AGREEMENT AMENDS AND RESTATES THAT CERTAIN EX-US COMMERCIALIZATION AGREEMENT, EFFECTIVE AS OF APRIL 7, 2015.FOUNDATION MEDICINE- PER AGREEMENT, ROCHE HAS EXCLUSIVE RIGHT IN TERRITORY TO COMMERCIALIZE CO'S CLINICAL DIAGNOSTIC TESTING COMMERCIAL PRODUCTS.FOUNDATION MEDICINE INC - INITIAL TERM OF AGREEMENT EXPIRES ON APRIL 7, 2020 AND MAY BE EXTENDED BY ROCHE FOR ADDITIONAL TWO-YEAR PERIODS.  Full Article

Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
Tuesday, 16 Jan 2018 07:00am EST 

Jan 16 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO.FOUNDATION MEDICINE - PARTNERSHIP FOCUSES ON DEVELOPMENT, REGULATORY SUPPORT AND COMMERCIALIZATION OF COMPANION DIAGNOSTICS.FOUNDATION MEDICINE - CENTERS FOR MEDICARE & MEDICAID SERVICES ISSUED PRELIMINARY NATIONAL COVERAGE DETERMINATION FOR FOUNDATIONONE CDX.FOUNDATION MEDICINE INC - FINAL POLICY FOR FOUNDATIONONE CDX IS EXPECTED TO ISSUE DURING Q1 OF 2018.  Full Article

Foundation Medicine Reports Preliminary 2017 Results
Monday, 8 Jan 2018 06:30am EST 

Jan 8 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE REPORTS PRELIMINARY 2017 RESULTS.- ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​.- ‍ PRELIMINARY UNAUDITED TOTAL REVENUE OF APPROXIMATELY $48.9 MILLION FOR Q4 OF 2017​.Q4 REVENUE VIEW $39.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $142.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Foundation Medicine Q3 loss per share $0.90
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 third quarter results and recent highlights.Q3 loss per share $0.90.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $42.7 million versus I/B/E/S view $38 million.Q3 earnings per share view $-1.10 -- Thomson Reuters I/B/E/S.  Full Article

Foundation Medicine receives approval from state of New York for foundation act liquid biopsy assay
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Foundation Medicine Inc : :Foundation Medicine Inc - receives approval from state of New York for foundation act liquid biopsy assay.  Full Article

Foundation Medicine and Roche enters into a fifth amendment to Collaboration Agreement
Wednesday, 13 Sep 2017 04:49pm EDT 

Sept 13 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - On September 8, company and Roche entered into a fifth amendment to Collaboration Agreement - SEC filing.Foundation Medicine Inc- Amendment reduced certain exclusivity provisions relating to blood-based tumor mutational burden assays.  Full Article

Foundation Medicine entered into amendment letter agreement with Roche Finance
Tuesday, 1 Aug 2017 04:36pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine Inc - co entered into amendment letter agreement with Roche Finance Ltd amending credit facility agreement, dated August 2, 2016.Foundation Medicine - amendment amends existing credit facility to provide for extension of period during which co may borrow funds from 3 to 4 yrs.Foundation Medicine Inc - amendment increases available funds from $100 million to $200 million - SEC filing.  Full Article

Foundation Medicine Q2 revenue $35 mln
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 second quarter results and recent highlights.Q2 loss per share $1.24.Q2 revenue $35 million versus I/B/E/S view $34.9 million.Sees FY 2017 revenue $135 million to $145 million.Q2 earnings per share view $-1.11 -- Thomson Reuters I/B/E/S.Foundation Medicine Inc - company is increasing clinical volume guidance and now expects to deliver between 61,000 and 64,000 clinical tests in 2017.Foundation Medicine Inc - increasing operating expenses and now expects they will be in range of $215 million and $225 million for 2017.FY 2017 revenue view $138.2 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Foundation Medicine - Co, Guardant Health ‍Announced Agreement To Settle False Advertising Challenges

* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ‍ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)